Patent · US Active

Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations

US9801823B2 · kind B2 · utility

13Cited by

36References

12Claims

0Family size

Assignee

Rhodes Pharmaceuticals L.P. · US

Inventors

Thinnayam N. Krishnamurthy · Scarborough, CA
Andrew Darke · Schreiber, CA

Key dates

Filing date	May 21, 2015
Grant date	Oct 31, 2017
Priority date	—
Expiry date	May 21, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.